BeiGene
As of the edition of 20 October 2026, BeiGene runs 30 drugs, 3 of them marketed; it is on route A at 6 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
BeiGene was renamed in 2025.
The records place 5 company names in this family.
- BeiGene, Ltd.: renamed in 2025
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 9 |
| Stopped | 10 |
| Status not established | 8 |
| Total | 30 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tislelizumab | Ends 2036 (computed from the first US licence) | 2 |
| Zanubrutinib | Ends 2037 (patent) | 1 |
| Sonrotoclax | Ends 2039 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 6 targets, route B at 3 targets.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where BeiGene needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 96 trials led
- Immune system: 45 trials led
- Blood and lymph: 43 trials led